Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

These two studies, one in type 1 diabetes patients and the other in type 2 patients, will each enroll approximately 110 patients. The primary endpoint will be a comparison of glycemic control, as assessed by the change in A1C from baseline.
  • An equity financing raised net proceeds of $60 million through a public offering of 8.3 million newly issued shares of common stock. The offering closed on September 14, 2010.
  • Halozyme completed its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. We have been in communication with the U.S. Food and Drug Administration (FDA), and have provided them materials relating to the root cause and remediation plans.
  • Recently, Halozyme redirected its resources to concentrate on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and to support its strategic alliances with Roche and Baxter. Halozyme will continue full development of its Phase 2 Ultrafast Insulin, Phase 1 PEGPH20, and preclinical HTI-501 programs, and has decreased research relating to the discovery and preclinical assessment of new compounds. This strategy resulted in reduction in the workforce of approximately 25 percent.
  • Baxter presented two posters with interim data from its Phase 3 clinical trial of HyQ at the European Society for Immunodeficiencies meeting in Istanbul, Turkey on October 6-9, 2010. HyQ is an immunoglobulin therapy facilitated subcutaneously by Halozyme's recombinant human hyaluronidase. Interim analyses showed that 28 out of 29 HyQ-treated study participants with primary immune deficiency were able to infuse immunoglobulin under the skin, using a single injection site, at infusion volumes, intervals and rates equivalent to their previous intravenous (IV) administration of immunoglobulin. 
  • Roche presented a poster of its Phase 1 clinical trial for Her
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... GEA Niro Soavi the leader in high ... PandaPLUS 2000, which is ideal for new applications for ... disruption . This compact laboratory homogenizer is the perfect ... food additives and ingredients as well as for the ...
    (Date:1/22/2015)... Rootstown, OH (PRWEB) January 22, 2015 Crystal ... announced today that it has received AOAC-PTM Certifications for the ... O111, O121, and O145; collectively referred to as STEC or ... at 1 colony forming unit (cfu) per 325 g of ...
    (Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
    (Date:1/22/2015)... Mass. , Jan. 22, 2015   GenoSpace , a ... of tools to enable the broad use of genomic, imaging ... announced the appointment of Michelle Munson , CEO of ... director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
    Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2
    ... ... of the prestigious eHealthcare Leadership Award given annually to organizations representing the best web ... ... leading provider of clinical trials information, received its fifth consecutive eHealthcare Leadership Award and ...
    ... GUANGZHOU, China, Nov. 11 /PRNewswire-Asia/ -- China ... "the Company"), a leading,developer and distributor of prescription ... nutritional and dietary supplements, and,medical devices and medical ... call at 10:00 a.m. Eastern Time on Monday, ...
    ... Pa., Nov. 9 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ... quarter ended September 30, 2009. , , Third ... to $33.6 million from $30.5 million in the prior year, ... particularly in, licensed products;, ...
    Cached Biology Technology:CenterWatch Honored a Fifth Consecutive Year for Best Healthcare Content 2China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results 2China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results 3BMP Sunstone Reports Third Quarter 2009 Financial Results 2BMP Sunstone Reports Third Quarter 2009 Financial Results 3BMP Sunstone Reports Third Quarter 2009 Financial Results 4BMP Sunstone Reports Third Quarter 2009 Financial Results 5BMP Sunstone Reports Third Quarter 2009 Financial Results 6BMP Sunstone Reports Third Quarter 2009 Financial Results 7BMP Sunstone Reports Third Quarter 2009 Financial Results 8BMP Sunstone Reports Third Quarter 2009 Financial Results 9BMP Sunstone Reports Third Quarter 2009 Financial Results 10BMP Sunstone Reports Third Quarter 2009 Financial Results 11BMP Sunstone Reports Third Quarter 2009 Financial Results 12
    (Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
    (Date:1/22/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the recent success of the Wocket™ smart wallet at CES 2015 ... wallet was named as one of the "11 Hot Products at CES" ... Launched At CES So Far" by Newseveryday.com and "The top 10 gadgets ...
    (Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
    Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
    ... new mechanism of infection for the most fatal bee ... which can kill entire colonies of bees. Every year, ... beekeepers all over the world. The only control measure ... of infection (pathogenic mechanism) was originally thought to be ...
    ... 1 Stinger Systems, Inc. (OTC,Bulletin Board: STIY), ... had reached a settlement agreement with the Securities ... settled the matter without admitting or,denying wrongdoing and ... Systems, Inc. also said that no fines or ...
    ... of physical oceanographers including a researcher from Scripps Institution ... oxygen-poor regions of tropical oceans are expanding as the ... and other marine organisms can live or enter in ... by Lothar Stramma from the Leibniz Institute of Marine ...
    Cached Biology News:Bees disease -- 1 step closer to finding a cure 2Oxygen depletion: A new form of ocean habitat loss 2
    ... Immunodepletion Kit specifically removes 20 of the ... serum in preparation for further proteomics analysis. ... plasma proteome whether you use one- or ... go straight to mass spectrometry. This is ...
    ... • Small design specifically for western ... ,Trays are specifically designed for staining western ... x 25 mm) of the disposable tray ... a significant cost savings to the user. ...
    ... the industry's first siRNA sequence design software ... keep these tools consistent with new experimental ... field of RNAi. With the introduction ... design tools, OligoEngine is pleased to offer ...
    ... The Gene Inspector can perform many sophisticated ... software is much more than just another sequence ... an entire suite of analyses to be performed ... to design custom style sheets which specify exactly ...
    Biology Products: